Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
RESEARCH TRIANGLE PARK, N.C., April 26, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its first quarter 2018 financial results will be reported on Tuesday, May 8, 2018.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at https://biocryst.gcs-web.com/events.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at https://biocryst.gcs-web.com/financial-information/sec-filings.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
